Relevant bibliographies by topics / Daclatasvir

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Daclatasvir'

Author: Grafiati
Published: 9 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Daclatasvir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Daclatasvir"

1

Sacramento, Carolina Q., Natalia Fintelman-Rodrigues, Jairo R. Temerozo, et al. "In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19." Journal of Antimicrobial Chemotherapy 76, no. 7 (2021): 1874–85. http://dx.doi.org/10.1093/jac/dkab072.

Full text
Abstract:
Abstract Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected
APA, Harvard, Vancouver, ISO, and other styles
2

Smith, Michael A., Randolph E. Regal, and Rima A. Mohammad. "Daclatasvir." Annals of Pharmacotherapy 50, no. 1 (2015): 39–46. http://dx.doi.org/10.1177/1060028015610342.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

CH., V. S. Gautam* N. Harika V. Balaji V. Srinivas Prasad. "METHOD DEVELOPMENT AND VALIDATION OF DACLATASVIR IN BULK & PHARMACEUTICAL DOSAGE FORM BY UV-VISIBLE SPECTROPHOTOMETRY." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 03 (2018): 1980–85. https://doi.org/10.5281/zenodo.1213232.

Full text
Abstract:
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of hepatitis-C drug - Daclatasvir in active pharmaceutical ingredient(API) form and in pharmaceutical dosage form Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir based on measurement of absorption at a wavelength maximum (λmax) of 317 nm using methanol as solvent. Results: The method was validated in terms of, precision, linearity, accuracy, and robustness
APA, Harvard, Vancouver, ISO, and other styles
4

Ravindra S Morey, Ganesh G Tapadiya, and Manisha V Doud. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. http://dx.doi.org/10.30574/wjarr.2024.23.2.2569.

Full text
Abstract:
A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Dihydrochlorid
APA, Harvard, Vancouver, ISO, and other styles
5

Ravindra, S. Morey, G. Tapadiya Ganesh, and V. Doud Manisha. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. https://doi.org/10.5281/zenodo.14891592.

Full text
Abstract:
A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Di
APA, Harvard, Vancouver, ISO, and other styles
6

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.036.10.1703570.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.36.10.1703570.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chakravarthy, V. Ashok, Sailaja Bbv, and Praveen Kumar A. "METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM." Asian Journal of Pharmaceutical and Clinical Research 9, no. 9 (2016): 61. http://dx.doi.org/10.22159/ajpcr.2016.v9s3.14616.

Full text
Abstract:
ABSTRACTObjective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitativeestimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir isbased on measurement of absorption at a wavelength maximum (λmax) of 317 and 261 nm using methanol as solvent.Results: The method was validated in terms of specificity, precision, linearity, a
APA, Harvard, Vancouver, ISO, and other styles
9

SHULPEKOVA, Y. O., N. V. SHULPEKOVA, M. C. SEMENISTAYA, A. A. USANOVA, and C. S. PAVLOV. "TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR." Medical Council, no. 4 (May 26, 2017): 36–41. http://dx.doi.org/10.21518/2079-701x-2017-4-36-41.

Full text
Abstract:
The purpose of the review is to evaluate the efficacy and safety of using pangenotypic combination «of Sofosbuvir/Daclatasvir» — the direct action antiviral drugs in the treatment of chronic HCV infection at different stages of liver damage.Main provisions: Sofosbuvir is the antisense nucleotide, inhibiting RNA-dependent RNA-polymerase NS5B, this drug has earned a reputation as one of the strongest anti-replication drugs, including when there is interferon resistance. Daclatasvir is a powerful non-nucleotide inhibitor of NS5А protein, catalyzing formation of replicative complexes. Both compone
APA, Harvard, Vancouver, ISO, and other styles
10

Ahmad Ather, Ch Adnan, Mariyam Nawaz, Sohail Bashir Sulehria, Saadia Chaudary, Zara Mehmood, and Maria Rehman. ""TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OFHEPATITIS C VIRUS"." Journal of Akhtar Saeed Medical & Dental College 05, no. 02 (2023): 90–96. https://doi.org/10.51127/jamdcv5i2oa05.

Full text
Abstract:
Background:To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.Material and Methods:Total 180 patients meeting inclusion criteria were enrolled in the studyfromDepartment of Medicine, Government Teaching Hospital Shahdara, Lahore.This randomized controlled trial was conducted fromMarch 25, 2021,to September 24, 2021.Treatment naive cases were given tablet sofosbuvir & daclatasvir for 12 weeks. Treatment-experienced and naive with cirrhosis were given ribavirin based on their body weight along with sofosbuvir and daclatasv
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Daclatasvir"

1

BARROS, Luciana Tavares de Carvalho. "Avaliação da eficácia e segurança do daclatasvir e sofosbuvir versus alfapeginterferona 2A no tratamento da hepatite C crônica." Universidade Federal de Pernambuco, 2016. https://repositorio.ufpe.br/handle/123456789/24772.

Full text
Abstract:
Submitted by Alice Araujo (alice.caraujo@ufpe.br) on 2018-06-05T18:24:22Z No. of bitstreams: 1 DISSERTAÇÃO Luciana Tavares de Carvalho Barros.pdf: 978217 bytes, checksum: 9bbd97bc0d108d6999496e25f30b47df (MD5)<br>Made available in DSpace on 2018-06-05T18:24:22Z (GMT). No. of bitstreams: 1 DISSERTAÇÃO Luciana Tavares de Carvalho Barros.pdf: 978217 bytes, checksum: 9bbd97bc0d108d6999496e25f30b47df (MD5) Previous issue date: 2016-06-09<br>A Hepatite C representa um grande impacto na saúde pública em todo o mundo. Interfere na vida dos portadores de HCV, na sociedade, no sistema de saúde e n
APA, Harvard, Vancouver, ISO, and other styles
2

Grimm, Christian [Verfasser], Robert [Gutachter] Tampé, and Christoph [Gutachter] Welsch. "Charakterisierung des Lipidbindungsverhaltens und der Proteinfaltung von HCV NS5A unter Einfluss des NS5A-Inhibitors Daclatasvir / Christian Grimm ; Gutachter: Robert Tampé, Christoph Welsch." Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg, 2021. http://d-nb.info/1239730276/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jarek, Nayara Almeida de Assis. "Análise de custo-efetividade do tratamento precoce da hepatite viral C crônica com simeprevir, daclatasvir e sofosbuvir sob a perspectiva do Sistema Único de Saúde." reponame:Repositório Institucional da UFPR, 2017. http://hdl.handle.net/1884/53663.

Full text
Abstract:
Orientador : Prof. Dr. Roberto Pontarolo<br>Coorientadora : Drª. Inajara Rotta<br>Dissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências da Saúde, Programa de Pós-Graduação em Ciências Farmacêuticas. Defesa: Curitiba, 22/09/2017<br>Inclui referências : f. 83-93<br>Resumo: A hepatite viral C crônica é causada pelo vírus da hepatite C (VHC) e os indivíduos são considerados curados após atingir a resposta virológica sustentada (RVS). Porém, os elevados custos dificultam o acesso às terapias disponíveis. Dados os recursos limitados, a inserção de novas terapias deve ter sua via
APA, Harvard, Vancouver, ISO, and other styles
4

REGHELLIN, VERONICA. "Studies on the mechanism of action of antiviral agents targeting the replication complex of hepatitis c virus." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2014. http://hdl.handle.net/10281/52708.

Full text
Abstract:
At the moment, several companies are studying the clinical potential of different all-oral combinations of direct-acting antivirals in ongoing studies. The most promising interferon-free combination therapies that are on the horizon include linear or cyclic NS3/4A protease inhibitors, nucleoside as well as non-nucleoside NS5B polymerase inhibitors , and NS5A inhibitors. DAAs that target NS3/4A (protease) and NS5B (RNA-dependent RNA polymerase) inhibit the enzymatic activity of these proteins. NS5A replication complex inhibitors will likely form a component of future interferon-free dru
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Hsuan-Yi, and 陳宣怡. "All-Oral Direct-Acting Agent Daclatasvir Plus Asunaprevir for Chronic Genotype 1b Hepatitis C Virus Infection Patients: Real-World Experience of Virologic Response and Side Effects." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/2m99sr.

Full text
Abstract:
碩士<br>中山醫學大學<br>醫學研究所<br>104<br>Introduction: All-oral direct-acting agent dual therapy with Daclatasvir plus Asunaprevir (DCV+ASV) achieved high sustained virological responses (SVR) in genotype 1b (GT-1b) HCV patients in the HALLMARK-DUAL1 study and Phase 3 Japanese study2,3. DCV + ASV is approved in several countries including Taiwan in March, 2016, Japan, Korea, and Latin America, Eastern Europe. In this study, real-world experience of DCV+ASV dual therapy in HCV GT-1b patients was reported. Purpose: To evaluate the efficacy and safety of DCV+ASV therapy in GT-1b HCV infected Taiwanese pat
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Daclatasvir"

1

Blokdijk, G. J. Daclatasvir Dihydrochloride; A Clear and Concise Reference. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Daclatasvir"

1

Belema, Makonen, Shawn K. Pack, and Nicholas A. Meanwell. "Daclatasvir (Daklinza): The First-in-Class HCV NS5A Replication Complex Inhibitor." In Innovative Drug Synthesis. John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118819951.ch3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mitsui, Fukiko, C. Nelson Hayes, Fumitaka Suzuki, and Kazuaki Chayama. "The Efficacy of Daclatasvir Plus Asunaprevir Combination Therapy with Chronic Hepatitis." In Hepatitis C Virus Treatment. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2416-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Meanwell, Nicholas A., and Makonen Belema. "The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex." In Topics in Medicinal Chemistry. Springer International Publishing, 2019. http://dx.doi.org/10.1007/7355_2018_47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"DAKLINZA (Daclatasvir)." In Antibiotics Manual. John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Belema, Makonen, Steven M. Schnittman, and Nicholas A. Meanwell. "Case History: The Discovery of the First Hepatitis C Virus NS5A Replication Complex Inhibitor Daclatasvir (Daklinza™)." In Medicinal Chemistry Reviews. Medicinal Chemistry Division of the American Chemical Society, 2016. http://dx.doi.org/10.29200/acsmedchemrev-v51.ch22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

VOLKWEIS, J. G., A. C. C. SANCHES, O. D. BOEIRA JUNIOR, and J. A. D. HORVATH. "AVALIAÇÃO DO USO E ANÁLISE DE CUSTOS DOS MEDICAMENTOS SOFOSBUVIR, SIMEPREVIR, DACLATASVIR PARA TRATAMENTO DA HEPATITE VIRAL CRÔNICA TIPO C DO COMPONENTE ESPECIALIZADO DA ASSISTÊNCIA FARMACÊUTICA NO MUNICÍPIO DE CASCAVEL - PR." In Diálogos entre Enfermagem e Farmácia: – Volume 1. Dialética, 2023. http://dx.doi.org/10.48021/978-65-270-0772-2-c4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Daclatasvir"

1

Nimie, Hemlata M., and Minakshi N. Deodhar. "Method Development and Force Degradation Study for Daclatasvir Using LC-MS/MS." In 2020 Advances in Science and Engineering Technology International Conferences (ASET). IEEE, 2020. http://dx.doi.org/10.1109/aset48392.2020.9118229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pajin, R. Madera, R. Asensi Diez, L. Yunquera Romero, JC Del Rio Valencia, and I. Muñoz Castillo. "DI-044 Effectiveness of the combination sofosbuvir and daclatasvir for the treatment of hepatitis C virus infection." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.291.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Daclatasvir"

1

Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin, and Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.

Full text
Abstract:
Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplemen
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Daclatasvir' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography